Skip to main content
Premium Trial:

Request an Annual Quote

MediChem Awarded NIH Grant to Further Protein Crystallization Effort

NEW YORK, June 13 – Medichem Life Sciences’ Emerald BioStructures division was awarded a Phase II grant from the National Institutes of Health for development of protein crystallization tools, the company announced Wednesday.

The SBIR Phase II grant follows a Phase I grant that supported Emerald’s development of its EmeraldEngine protein crystallization technology platform, which includes robotic automation, software and databases, and expression and membrane crystallization technologies. The Phase II grant is titled “Crystallization Tools for Structural Genomics.”

“Protein crystallization is currently the rate-limiting step in structural proteomics,” MediChem CEO Michael Flavin said in a statement. “Our proprietary technologies enable us to crystallize proteins faster than ever before. This Phase II grant will fund the development of technologies that speed up the process even more.” 

After protein crystallization, Emerald, via a proprietary user agreement, uses Argonne National Laboratory’s Advanced Photon Source to collect X-ray diffraction data and obtain a high resolution rendering of the proteins’ three-dimensional structures.

Chicago-based MediChem acquired Emerald in June 2000. The size of the grant was not disclosed.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.